Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Research & Development (2016 - 2025)

Historic Research & Development for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $4.2 million.

  • Abeona Therapeutics' Research & Development fell 5284.64% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year decrease of 1114.98%. This contributed to the annual value of $34.4 million for FY2024, which is 1051.43% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Research & Development stood at $4.2 million, which was down 5284.64% from $5.9 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Research & Development high stood at $12.8 million for Q4 2021, and its period low was $4.2 million during Q3 2025.
  • Over the past 5 years, Abeona Therapeutics' median Research & Development value was $8.3 million (recorded in 2021), while the average stood at $8.1 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 3967.92% in 2021, then tumbled by 5284.64% in 2025.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Research & Development stood at $12.8 million in 2021, then tumbled by 51.01% to $6.3 million in 2022, then rose by 17.65% to $7.4 million in 2023, then grew by 21.89% to $9.0 million in 2024, then plummeted by 53.12% to $4.2 million in 2025.
  • Its Research & Development stands at $4.2 million for Q3 2025, versus $5.9 million for Q2 2025 and $9.9 million for Q1 2025.